Clinical trials
catalyst calendar across sponsors →Studies where TARA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
6 interventional · 1 observational
Held by 13 tracked-famous managers (MILLENNIUM MANAGEMENT LLC, CITADEL ADVISORS LLC, Qube Research & Technologies Ltd, Balyasny Asset Management L.P., MARSHALL WACE, LLP, +8 more) · FINRA short interest 11.5 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder CancerNCT05951179Cohort A and B: Incidence of high-grade Complete Response at any time according to central pathology after treatment with TARA-002Open-label · Treatment | Phase 2 | Recruiting | Biological: TARA-002 | Non-muscle Invasive Bladder Cancer | 131 | Oct 2031 | ≤ 1,899 d | 2026-06-30 |
| Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder CancerNCT07480356Incidence of high-grade complete responseRandomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: TARA-002, Investigator's Choice of Intravesical Chemotherapy | Bladder (Urothelial, Transitional Cell) Cancer, Non-Muscle Invasive Bladder Carcinoma, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ | 284 | Apr 2028 | ≤ 620 d | 2026-06-29 |
| Study of Choline Chloride for Injection in Adolescent and Adult Patients With Intestinal Failure Receiving Long Term Parenteral SupportNCT06910943Open-Label Dose-Selection Phase: PK of plasma free choline (Cmax) during Week 1 and Week 8 VisitsRandomized · Triple-masked · Treatment | Phase 2/3 | Recruiting | Drug: Choline Chloride for Injection, Placebo | Choline Deficiency, Liver Injury | 129 | Jun 2027 | ≤ 315 d | 2026-06-29 |
| Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of AgeNCT05871970Proportion of participants with clinical success after one treatment cycle of TARA-002Open-label · Treatment | Phase 2 | Recruiting | Biological: TARA-002 | Lymphatic Malformation | 38 | Dec 2026 | ≤ 134 d | 2026-05-18 |
| Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1b)NCT05085990Phase 1b, Dose Expansion Phase: Incidence of AEs in subjects with CIS NMIBC with active diseaseOpen-label · Treatment | Phase 1 | Completed | Biological: TARA-002 | Non-muscle Invasive Bladder Cancer | 10 | 2024-09-12actual | — | 2025-01-27 |
| Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1a)NCT05085977Phase 1a, Dose Escalation Phase: Incidence of DLT AEs in subjects with HGTa or CIS NMIBCOpen-label · Treatment | Phase 1 | Completed | Biological: TARA-002 | Non-muscle Invasive Bladder Cancer | 12 | 2024-09-03actual | — | 2025-01-27 |
| Prevalence of Liver Disease in Patients Dependent on Parenteral NutritionNCT05011370observationalPercentage of patients with choline deficiency | — | Completed | — | Intestinal Failure-associated Liver Disease | 80 | 2023-06-29actual | — | 2023-10-03 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19